Profitability Ratios
| Ratio |
Value |
| GP Margin |
94.0% |
| EBIT Margin |
-70.0% |
| EBITDA Margin |
-64.4% |
| Operating Margin |
-70.0% |
| Pretax Margin |
-64.2% |
| Cont. Ops Margin |
-102.0% |
| Net Margin |
-102.0% |
| Bottom Line Margin |
-102.0% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.39 |
| Quick Ratio |
2.38 |
| Solvency Ratio |
-1.289 |
| Cash Ratio |
0.58 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.00 |
| Forward PEG |
-0.00 |
| Price/Book |
1.59 |
| Price/Sales |
2.41 |
| Price/FCF |
-4.71 |
| Price/Op Cash Flow |
-4.75 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.0258 |
| Debt/Equity |
0.0386 |
| Debt/Capital |
0.0371 |
| Long-Term Debt/Capital |
0.0000 |
| Financial Leverage |
1.49 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.80 |
| Operating Cash Flow Ratio |
-0.754 |
| Operating Cash Flow/Sales |
-50.6% |
| Free Cash Flow/Operating Cash Flow |
100.9% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
0.00 |
| Interest Coverage |
0.0000 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
-8.67 |
| Capital Expenditure Coverage |
-109.66 |
| Dividend + Capital Expenditure Coverage |
-109.66 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
3.67 |
| EPS |
-3.741 |
| Debt/Share |
0.2142 |
| Cash/Share |
4.48 |
| Book Value/Share |
5.55 |
| Tangible BV/Share |
3.57 |
| Equity/Share |
5.55 |
| Operating Cash Flow/Share |
-1.857 |
| Capital Expenditure/Share |
0.017 |
| FCF/Share |
-1.874 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.590 |
| Earnings Before Tax/EBIT |
0.917 |
| Price/Fair Value |
1.59 |
| Debt/Market Cap |
0.0000 |
| Effective Tax Rate |
-59.0% |
| Enterprise Value Multiple |
-3.21 |
VNDA - Vanda Pharmaceuticals Inc.